CoChat

Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis

Open access
Kozumi, Kazuhiro, Kodama, Takahiro, Murai, Hiroki, Sakane, Sadatsugu, Govaere, Olivier, Cockell, Simon, Motooka, Daisuke, Kakita, Naruyasu, Yamada, Yukinori, Kondo, Yasuteru, Tahata, Yuki, Yamada, Ryoko, Hikita, Hayato, Sakamori, Ryotaro, Kamada, Yoshihiro, Daly, Ann K., Anstee, Quentin M., Tatsumi, Tomohide, Morii, Eiichi, Takehara, Tetsuo · 2021 · Hepatology
Cited by 164

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Background and Aims: NAFLD is the most common liver disease worldwide. NASH, the progressive form of NAFLD, and advanced fibrosis are associated with poor outcomes. We searched for their noninvasive biomarkers. Approach and Results: Global RNA sequencing of liver tissue from 98 patients with biopsy‐proven NAFLD was performed. Unsupervised hierarchical clustering well distinguished NASH from nonalcoholic fatty liver (NAFL), and patients with NASH exhibited molecular abnormalities reflecting their pathological features. Transcriptomic analysis identified proteins up‐regulated in NASH and/or advanced fibrosis (stage F3‐F4), including matricellular glycoprotein thrombospondin‐2 (TSP‐2), encoded by the thrombospondin 2 (THBS2) gene. The intrahepatic THBS2 expression level showed the highest areas under the receiver operating characteristic curves (AUROCs) of 0.915 and 0.957 for diagnosing NASH and advanced fibrosis, respectively. THBS2 positively correlated with inflammation and ballooning according to NAFLD activity score, serum aspartate aminotransferase and hyaluronic acid (HA) levels, and NAFLD Fibrosis Score (NFS). THBS2 was associated with extracellular matrix and collagen biosynthesis, platelet activation, caspase‐mediated cleavage of cytoskeletal proteins, and immune cell infiltration. Serum TSP‐2 expression was measured in 213 patients with biopsy‐proven NAFLD, was significantly higher in NASH than in NAFL, and increased parallel to fibrosis stage. The AUROCs for predicting NASH and advanced fibrosis were 0.776 and 0.856, respectively, which were comparable to Fibrosis‐4 index, serum HA level, and NFS in advanced fibrosis diagnosis. Serum TSP‐2 level and platelet count were independent predictors of NASH and advanced fibrosis. Serum TSP‐2 levels could stratify patients with NAFLD according to the risk of hepatic complications, including liver cancer and decompensated cirrhotic events. Conclusions: TSP‐2 may be a useful biomarker for NASH and advanced fibrosis diagnosis in patients with NAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.31995

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 164

Metadata

Authors
Kozumi, K., Kodama, T., Murai, H., Sakane, S., Govaere, O., Cockell, S., Motooka, D., Kakita, N., Yamada, Y., Kondo, Y., Tahata, Y., Yamada, R., Hikita, H., Sakamori, R., Kamada, Y., Daly, A. K., Anstee, Q. M., Tatsumi, T., Morii, E., & Takehara, T.
Venue
Hepatology
Published
2021-08-21
Volume
74
Issue
5
Pages
2452-2466
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W3160822742
Cited by
164
References
13
FWCI
16.39
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis. https://app.cochat.ai/papers/10.1002/hep.31995
The paper
Kozumi, K., Kodama, T., Murai, H., Sakane, S., Govaere, O., Cockell, S., Motooka, D., Kakita, N., Yamada, Y., Kondo, Y., Tahata, Y., Yamada, R., Hikita, H., Sakamori, R., Kamada, Y., Daly, A. K., Anstee, Q. M., Tatsumi, T., Morii, E., & Takehara, T. (2021). Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis. Hepatology. https://doi.org/10.1002/hep.31995

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.